BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 10229082)

  • 1. An IL-2 receptor beta subdomain that controls Bcl-X(L) expression and cell survival.
    Ciprés A; Gala S; Martinez-A C; Mérida I; Williamson P
    Eur J Immunol; 1999 Apr; 29(4):1158-67. PubMed ID: 10229082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The IL-2 receptor promotes lymphocyte proliferation and induction of the c-myc, bcl-2, and bcl-x genes through the trans-activation domain of Stat5.
    Lord JD; McIntosh BC; Greenberg PD; Nelson BH
    J Immunol; 2000 Mar; 164(5):2533-41. PubMed ID: 10679091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cooperation between STAT5 and phosphatidylinositol 3-kinase in the IL-3-dependent survival of a bone marrow derived cell line.
    Rosa Santos SC; Dumon S; Mayeux P; Gisselbrecht S; Gouilleux F
    Oncogene; 2000 Feb; 19(9):1164-72. PubMed ID: 10713704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissociation of cytokine signals for proliferation and apoptosis.
    Shi Y; Wang R; Sharma A; Gao C; Collins M; Penn L; Mills GB
    J Immunol; 1997 Dec; 159(11):5318-28. PubMed ID: 9548471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of STAT1, STAT3 and STAT5 proteins with the IL-2 receptor involves different subdomains of the IL-2 receptor beta chain.
    Delespine-Carmagnat M; Bouvier G; Bertoglio J
    Eur J Immunol; 2000 Jan; 30(1):59-68. PubMed ID: 10602027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-3 dependent regulation of Bcl-xL gene expression by STAT5 in a bone marrow derived cell line.
    Dumon S; Santos SC; Debierre-Grockiego F; Gouilleux-Gruart V; Cocault L; Boucheron C; Mollat P; Gisselbrecht S; Gouilleux F
    Oncogene; 1999 Jul; 18(29):4191-9. PubMed ID: 10435632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-apoptotic signaling by the interleukin-2 receptor reveals a function for cytoplasmic tyrosine residues within the common gamma (gamma c) receptor subunit.
    Lindemann MJ; Benczik M; Gaffen SL
    J Biol Chem; 2003 Mar; 278(12):10239-49. PubMed ID: 12525482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The IL-2 receptor promotes proliferation, bcl-2 and bcl-x induction, but not cell viability through the adapter molecule Shc.
    Lord JD; McIntosh BC; Greenberg PD; Nelson BH
    J Immunol; 1998 Nov; 161(9):4627-33. PubMed ID: 9794391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells.
    Hoover RR; Gerlach MJ; Koh EY; Daley GQ
    Oncogene; 2001 Sep; 20(41):5826-35. PubMed ID: 11593388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of STAT5 triggers proliferation and contributes to anti-apoptotic signalling mediated by the oncogenic Xmrk kinase.
    Morcinek JC; Weisser C; Geissinger E; Schartl M; Wellbrock C
    Oncogene; 2002 Mar; 21(11):1668-78. PubMed ID: 11896598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-2 (IL-2) receptor-betagamma signalling is activated by c-Kit in the absence of IL-2, or by exogenous IL-2 via JAK3/STAT5 in human papillomavirus-associated cervical cancer.
    Rocha-Zavaleta L; Huitron C; Cacéres-Cortés JR; Alvarado-Moreno JA; Valle-Mendiola A; Soto-Cruz I; Weiss-Steider B; Rangel-Corona R
    Cell Signal; 2004 Nov; 16(11):1239-47. PubMed ID: 15337523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiapoptotic activity of Stat5 required during terminal stages of myeloid differentiation.
    Kieslinger M; Woldman I; Moriggl R; Hofmann J; Marine JC; Ihle JN; Beug H; Decker T
    Genes Dev; 2000 Jan; 14(2):232-44. PubMed ID: 10652277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-7 reconstitutes multiple aspects of v-Abl-mediated signaling.
    Banerjee A; Rothman P
    J Immunol; 1998 Nov; 161(9):4611-7. PubMed ID: 9794389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells.
    Nosaka T; Kawashima T; Misawa K; Ikuta K; Mui AL; Kitamura T
    EMBO J; 1999 Sep; 18(17):4754-65. PubMed ID: 10469654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-2 inhibits glucocorticoid receptor transcriptional activity through a mechanism involving STAT5 (signal transducer and activator of transcription 5) but not AP-1.
    Biola A; Lefebvre P; Perrin-Wolff M; Sturm M; Bertoglio J; Pallardy M
    Mol Endocrinol; 2001 Jul; 15(7):1062-76. PubMed ID: 11435608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins.
    Scheijen B; Ngo HT; Kang H; Griffin JD
    Oncogene; 2004 Apr; 23(19):3338-49. PubMed ID: 14981546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of interleukin-3-induced gene expression by a C-terminal truncated Stat5: role of Stat5 in proliferation.
    Mui AL; Wakao H; Kinoshita T; Kitamura T; Miyajima A
    EMBO J; 1996 May; 15(10):2425-33. PubMed ID: 8665850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Signal transduction mediated by the reconstituted IL-2 receptor. Evidence for a cell type-specific function of IL-2 receptor beta-chain.
    Minami Y; Oishi I; Liu ZJ; Nakagawa S; Miyazaki T; Taniguchi T
    J Immunol; 1994 Jun; 152(12):5680-90. PubMed ID: 8207200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Convergence of signaling transduced by prolactin (PRL)/cytokine chimeric receptors on PRL-responsive gene transcription.
    Ferrag F; Chiarenza A; Goffin V; Kelly PA
    Mol Endocrinol; 1996 Apr; 10(4):451-60. PubMed ID: 8721989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-4 selectively inhibits IL-2-triggered Stat5 activation, but not proliferation, in human T cells.
    Castro A; Sengupta TK; Ruiz DC; Yang E; Ivashkiv LB
    J Immunol; 1999 Feb; 162(3):1261-9. PubMed ID: 9973378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.